Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 26.64 Billion JPY | 278.23% |
| 2023 | -14.94 Billion JPY | -154.92% |
| 2022 | 27.21 Billion JPY | 298.51% |
| 2021 | 6.83 Billion JPY | -71.08% |
| 2020 | 23.61 Billion JPY | -26.09% |
| 2019 | 31.95 Billion JPY | -9.38% |
| 2018 | 35.26 Billion JPY | 62.31% |
| 2017 | 21.72 Billion JPY | -59.3% |
| 2016 | 53.37 Billion JPY | 122.09% |
| 2015 | 24.03 Billion JPY | 21.88% |
| 2014 | 19.71 Billion JPY | 19.36% |
| 2013 | 16.52 Billion JPY | -3.73% |
| 2012 | 17.16 Billion JPY | -19.56% |
| 2011 | 21.33 Billion JPY | 13.95% |
| 2010 | 18.72 Billion JPY | 84.95% |
| 2009 | 10.12 Billion JPY | -19.98% |
| 2008 | 12.65 Billion JPY | -3.78% |
| 2007 | 13.14 Billion JPY | 0.96% |
| 2006 | 13.02 Billion JPY | 18.15% |
| 2005 | 11.02 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | 26.64 Billion JPY | 278.23% |
| 2024 Q1 | 10.41 Billion JPY | 833.15% |
| 2024 Q4 | 29 Million JPY | -99.6% |
| 2024 Q3 | 7.33 Billion JPY | -17.3% |
| 2024 Q2 | 8.86 Billion JPY | -14.86% |
| 2023 Q1 | 6.66 Billion JPY | -15.89% |
| 2023 Q3 | 5.97 Billion JPY | 120.82% |
| 2023 FY | -14.94 Billion JPY | -154.92% |
| 2023 Q4 | 1.11 Billion JPY | -81.33% |
| 2023 Q2 | -28.71 Billion JPY | -530.95% |
| 2022 Q3 | 5.04 Billion JPY | -27.22% |
| 2022 Q2 | 6.92 Billion JPY | -5.64% |
| 2022 Q1 | 7.34 Billion JPY | 152.01% |
| 2022 Q4 | 7.92 Billion JPY | 57.12% |
| 2022 FY | 27.21 Billion JPY | 298.51% |
| 2021 Q1 | 6.18 Billion JPY | 85.3% |
| 2021 FY | 6.83 Billion JPY | -71.08% |
| 2021 Q3 | 7.12 Billion JPY | -5.89% |
| 2021 Q4 | -14.11 Billion JPY | -298.01% |
| 2021 Q2 | 7.57 Billion JPY | 22.39% |
| 2020 FY | 23.61 Billion JPY | -26.09% |
| 2020 Q4 | 3.34 Billion JPY | -53.28% |
| 2020 Q3 | 7.14 Billion JPY | 6.08% |
| 2020 Q1 | 6.39 Billion JPY | -25.38% |
| 2020 Q2 | 6.73 Billion JPY | 5.31% |
| 2019 Q4 | 8.57 Billion JPY | -4.62% |
| 2019 FY | 31.95 Billion JPY | -9.38% |
| 2019 Q1 | 6.85 Billion JPY | -13.41% |
| 2019 Q2 | 7.52 Billion JPY | 9.82% |
| 2019 Q3 | 8.99 Billion JPY | 19.48% |
| 2018 Q2 | 6.23 Billion JPY | -30.84% |
| 2018 FY | 35.26 Billion JPY | 62.31% |
| 2018 Q4 | 7.91 Billion JPY | -34.61% |
| 2018 Q3 | 12.1 Billion JPY | 94.16% |
| 2018 Q1 | 9.01 Billion JPY | 177.98% |
| 2017 FY | 21.72 Billion JPY | -59.3% |
| 2017 Q4 | 3.24 Billion JPY | -55.05% |
| 2017 Q3 | 7.21 Billion JPY | 39.17% |
| 2017 Q2 | 5.18 Billion JPY | -29.24% |
| 2017 Q1 | 7.32 Billion JPY | 110.07% |
| 2016 Q4 | 3.48 Billion JPY | -44.04% |
| 2016 Q2 | 36.11 Billion JPY | 378.93% |
| 2016 FY | 53.37 Billion JPY | 122.09% |
| 2016 Q1 | 7.54 Billion JPY | -3.84% |
| 2016 Q3 | 6.23 Billion JPY | -82.75% |
| 2015 FY | 24.03 Billion JPY | 21.88% |
| 2015 Q3 | 7.5 Billion JPY | 31.79% |
| 2015 Q1 | 4.06 Billion JPY | 134.56% |
| 2015 Q2 | 5.69 Billion JPY | 40.07% |
| 2015 Q4 | 7.84 Billion JPY | 4.5% |
| 2014 Q2 | 3.43 Billion JPY | -38.3% |
| 2014 Q3 | 6.38 Billion JPY | 85.96% |
| 2014 Q4 | 1.73 Billion JPY | -72.85% |
| 2014 FY | 19.71 Billion JPY | 19.36% |
| 2014 Q1 | 5.56 Billion JPY | 133.31% |
| 2013 Q1 | 4.27 Billion JPY | 78.65% |
| 2013 Q2 | 4.7 Billion JPY | 9.91% |
| 2013 Q3 | 5.15 Billion JPY | 9.72% |
| 2013 FY | 16.52 Billion JPY | -3.73% |
| 2013 Q4 | 2.38 Billion JPY | -53.78% |
| 2012 FY | 17.16 Billion JPY | -19.56% |
| 2012 Q4 | 2.39 Billion JPY | -50.75% |
| 2012 Q1 | 5.52 Billion JPY | -16.98% |
| 2012 Q3 | 4.86 Billion JPY | 11.01% |
| 2012 Q2 | 4.37 Billion JPY | -20.76% |
| 2011 Q1 | 4.57 Billion JPY | 84.37% |
| 2011 Q4 | 6.65 Billion JPY | 23.15% |
| 2011 FY | 21.33 Billion JPY | 13.95% |
| 2011 Q2 | 4.69 Billion JPY | 2.53% |
| 2011 Q3 | 5.4 Billion JPY | 15.15% |
| 2010 Q1 | 6.54 Billion JPY | 171.03% |
| 2010 FY | 18.72 Billion JPY | 84.95% |
| 2010 Q4 | 2.48 Billion JPY | -45.66% |
| 2010 Q2 | 5.12 Billion JPY | -21.78% |
| 2010 Q3 | 4.56 Billion JPY | -10.8% |
| 2009 FY | 10.12 Billion JPY | -19.98% |
| 2009 Q2 | 3.58 Billion JPY | 0.0% |
| 2009 Q3 | 3.98 Billion JPY | 11.04% |
| 2009 Q4 | 2.41 Billion JPY | -39.34% |
| 2008 FY | 12.65 Billion JPY | -3.78% |
| 2007 FY | 13.14 Billion JPY | 0.96% |
| 2006 FY | 13.02 Billion JPY | 18.15% |
| 2005 FY | 11.02 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | -347.389% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | -231.988% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -3106.34% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 47243.969% |
| Novartis AG | 14.85 Billion USD | -79.407% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -14725.364% |